A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Kinnate Biopharma

Status and phase: Active, not recruiting; Phase 1

Conditions: Solid Tumor, Adult; Urothelial Carcinoma; Intrahepatic Cholangiocarcinoma

Treatments: Drug: KIN-3248

Study type: Interventional

Funder types: Industry

Identifiers

NCT05242822

KN-4802

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.

Full description

This is a two-part, open label, multi-center, dose escalation and dose expansion study in participants with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.

Part A (dose escalation) is aimed at evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of KIN-3248, and determining the maximum tolerated dose (MTD) of daily dosing of KIN-3248.

Part B (dose expansion) may open once either the MTD and/or a biologically active dose of KIN-3248 is identified. Part B is aimed at evaluating the safety and efficacy of KIN-3248 at the recommended dose and schedule in participants with cancers harboring FGFR2 and/or FGFR3 gene alterations, including intrahepatic cholangiocarcinoma (ICC), urothelial cancer (UC), and other solid tumors.

Enrollment: 54 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provide written informed consent prior to initiation of any study-specific procedures
• Advanced stage solid tumor
• Known FGFR2 and/or FGFR3 gene alteration, as confirmed by previous genomic analysis of tumor tissue or ctDNA
• Measurable or evaluable disease according to RECIST v1.1
• ECOG performance status 0 or 1
• Adequate organ function, as measured by laboratory values (criteria listed in protocol)
• Able to swallow, retain, and absorb oral medications

Exclusion criteria

• Known clinically-active or clinically-progressive brain metastases from non-brain tumors
• History and/or current evidence of abnormal calcium-phosphorous homeostasis, ectopic mineralization or calcification, or corneal or retinal disorder/keratopathy
• GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease
• Active, uncontrolled bacterial, fungal, or viral infection
• Women who are lactating or breastfeeding, or pregnant

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

54 participants in 2 patient groups

Part A - dose escalation

Experimental group

Description:

Dose escalation of KIN-3248 in patients with solid tumors

Treatment:

Drug: KIN-3248

Part B - dose expansion

Experimental group

Description:

Dose expansion evaluating the recommended dose and schedule of KIN-3248 identified from Part A

Treatment:

Drug: KIN-3248